-transparent.png){kind=logo}
Outpatients with major affective disorder, unipolar depressed type (N=101), were treated in a 4-week placebo-controlled double-blind study to compare the efficacy and safety of fluvoxamine, a new serotonin reuptake inhibitor antidepressant, with imipramine and placebo. Therapy was initiated at 50 mg/day; thereafter, dosage ranged between 100 and 300 mg/day for both drugs. Results indicate statistically significant efficacy, measured by both patient and physician rating scales, for both active drugs over placebo. Fluvoxamine showed some evidence of earlier onset of action. Anticholinergic side effects were more common in the imipramine-treated patients, while fluvoxamine produced more gastrointestinal distress and insomnia.
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
January 1983,
British journal of clinical pharmacology,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
May 1990,
The Journal of clinical psychiatry,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
January 1980,
Proceedings of the annual meeting of the American Psychopathological Association,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
April 1996,
Journal of clinical psychopharmacology,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
December 1984,
Journal of affective disorders,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
June 1996,
International clinical psychopharmacology,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
March 1998,
International clinical psychopharmacology,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
January 1994,
Psychotherapy and psychosomatics,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
January 1983,
British journal of clinical pharmacology,
R A Dominguez, and
B J Goldstein, and
A F Jacobson, and
R M Steinbook
January 1990,
Current medical research and opinion,
